Analyst Price Target is $16.67
▲ +41.12% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Tango Therapeutics in the last 3 months. The average price target is $16.67, with a high forecast of $18.00 and a low forecast of $16.00. The average price target represents a 41.12% upside from the last price of $11.81.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in Tango Therapeutics. This Buy consensus rating has held steady for over two years.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.